Regeneron Pharmaceuticals, a biotechnology firm with a market capitalization of $68.8 billion headquartered in Tarrytown, New York, develops antibody-based treatments for serious diseases. The company is scheduled to release its second-quarter 2026 earnings results before market open on July 30.
Analysts anticipate the company will report earnings per share of $8, representing a 25.4% decline from the prior-year quarter’s $10.72 per share. However, Regeneron has maintained a track record of surpassing Wall Street’s bottom-line estimates in each of the last four quarters, which may temper concerns about the expected decline.
For the full fiscal year ending in December, consensus estimates call for $37.12 in per-share earnings, up 4.5% from $35.51 in fiscal 2025. Looking further ahead, analysts project earnings growth will accelerate to $42.26 per share in fiscal 2027, representing a 13.9% year-over-year increase.
The stock has appreciated 16.1% over the past 52 weeks, though this performance trails both the S&P 500 Index’s 18.9% return and the State Street Health Care Select Sector SPDR ETF’s 19.4% gain during the same period. In June, shares gained 2.9% following announcements of an expanded cancer therapy partnership with CytomX Therapeutics involving up to $4 billion in potential milestone payments and positive early-stage trial results for the rare disease treatment Lynozyfic.
Wall Street sentiment toward the stock remains positive overall, with analysts assigning a “Moderate Buy” rating. Among 30 analysts tracking the company, 19 recommend “Strong Buy,” two suggest “Moderate Buy,” and nine rate it “Hold.” The consensus price target stands at $828.59, implying potential upside of 27.2% from prevailing levels.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI